Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.
Oncology continues to be the leading therapeutic area for first launches by emerging biopharma companies in the United States. Recent ZS analysis identified 125 U.S. biopharma companies with first launches from 2011 to 2018, and 51 of those were for novel drugs. Of these 51,14 were in oncology—the largest number of any therapeutic area.
Dave Cohen co-authored this blog post with Sarah Hamilton.
With more than 650 new agents in development, oncology has been center stage for many pharmaceutical companies in recent years. Although unmet need remains high for many tumor types, this sizeable pipeline investment is expected to bring tremendous new promise to patients as drugs start hitting the market. Along with that promise, we suspect that it also will bring several commercial challenges for companies that are seeking to successfully launch an oncology asset into this new environment.